Vir Director Vicki Sato Sells Over 22,000 Shares

The transaction reflects part of a pre-arranged Rule 10b5-1 trading strategy set in early 2025.

January 06, 2026

Director Executes Planned Stock Sale

On January 2, 2026, Vicki L. Sato, a director at Vir Biotechnology, sold 22,000 shares of common stock through a scheduled trading plan. This plan—set in motion back in March 2025 under Rule 10b5-1—allows insiders to execute transactions at predetermined times, regardless of day-to-day market developments.

The shares were sold at an average price of approximately $5.93, with individual trades ranging from $5.84 to $6.09. The transaction was executed as part of a broader strategy to manage equity positions in line with regulatory safeguards. No additional trades involving derivative securities were reported.

Following the sale, Sato continues to hold more than 1.16 million shares directly. There were no changes to indirect holdings.

Regulatory Filing Confirms Compliance

The Form 4 filing, submitted on January 5, confirms that this transaction was carried out under an approved plan designed to comply with SEC guidelines. For investors and stakeholders, it’s another example of how public company insiders maintain transparency when managing their positions.

While stock sales like this are often routine, they still offer a window into how insiders are approaching their ownership. In this case, the action ties back to a plan that’s been in place for over nine months—designed to align with both disclosure requirements and personal portfolio goals.

For Vir, based in San Francisco, this update marks a procedural step forward—one that keeps shareholders informed and regulatory boxes checked.